PTEN and neoplasm: While the underlying basic mechanism of our patient's anti-tumor response remains uncertain, we suggest that further prospective studies are warranted to evaluate whether this combination therapy is effective in this population of patients with pre-treated mCRPC and <i>PTEN</i> loss.